top of page
RWE 2019 Projects
Subsequent Infusions
The Subsequent Infusions is a limited data collection project that is part of the retrospective de-identified data capture protocol, Outcomes in Pediatric and Young Adult B-Cell Acute Lymphoblastic Leukemia after Kymriah™ (Tisagenlecleucel) as an FDA-approved therapy.
Down Syndrome
This is a retrospective deidentified project through the PRWCC based out of Stanford, studying the outcomes of patients with down syndrome who received Kymriah in a real world setting.
Cytopenias
bottom of page